You can help make psychedelic therapy a legal treatment by donating to complete the second-largest study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), now nearing completion in Boulder, Colorado.
Your tax-deductible donation will be matched up to $7,000 by two generous donors (Bailey Gimbel and John McCormick). This offer ends on December 31, or when all matching funds have been met.
We have already raised $727,000 of the $771,000 needed for the Boulder study, with just $44,000 needed to complete the study.
Preliminary results from this study are showing that 56% of participants receiving MDMA-assisted psychotherapy experienced clinically significant (30% or more) decreases in PTSD symptoms two months after treatment, compared with only 17% of those receiving placebo. These results are even stronger one year after treatment, with 80% of participants experiencing significant improvements. This preliminary data reaffirms the promising results of our study published in 2011, which found that 83% of participants no longer had PTSD two months after treatment.
By making a gift today, you're helping make psychedelic therapy a legally available treatment.
Data from this and other Phase 2 studies will be used to plan the larger Phase 3 studies necessary to demonstrate to the FDA that MDMA-assisted psychotherapy is a safe and effective treatment for PTSD. We estimate needing an additional $870,000 to complete Phase 2, and an additional $22.1 million to complete Phase 3 and establish MDMA-assisted psychotherapy as a legally available treatment by 2021.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Since our founding in 1986, MAPS has disbursed over $23 million to psychedelic and medical marijuana research and education. Every dollar has come from visionary donors committed to our mission.